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Polycomb Group (PcG) proteins are transcriptional repressors that epigenetically modify chromatin and
participate in the establishment and maintenance of cell fates. These proteins play important roles in both
stem cell self-renewal and in cancer development. Our understanding of their mechanism of action has
greatly advanced over the past 10 years, but many unanswered questions remain. In this review, we present
the currently available experimental data that connect PcG protein function with some of the key processes
which govern somatic stem cell activity. We also highlight recent studies suggesting that a delicate balance
in PcG gene dosage is crucial for proper stem cell homeostasis and prevention of cancer stem cell
development.Stem Cells and Cancer
Throughout our lives, mature cells in adult tissues are continu-
ously replenished through the activity of small populations of
somatic stem cells. The defining feature of these cells is their
capacity to undergo self-renewal division coupled with mainte-
nance of multipotency. Somatic stem cells have been identified
for most tissues (blood, brain, muscle, skin, gut, etc.), and
harnessing their regenerative properties offers a great potential
for future therapies. At the molecular level, much about self-
renewal remains to be elucidated. However, we can envision
this process as the fine orchestration of cell-cycle regulation
with cell-fate decisions. To self-renew, stem cells must there-
fore enter the cell cycle and progress successfully through cell
division. During this process, genome integrity has to be pre-
served through the coordinated regulation of cell-cycle check-
points and DNA damage repair. While doing so, they must
also ensure that at least one daughter cell restricts programs
leading to differentiation, senescence, or apoptosis, thus retain-
ing stemness.
Accumulating evidence indicates that a subpopulation of
cancer cells within tumors possess stem cell-like properties.
Bonnet and Dick (1997) showed that most leukemic blasts are
limited in their proliferative capacity and must be constantly
replenished by a rare self-renewing population of ‘‘leukemic
stem cells.’’ Similar findings have been reported for cancers of
the breast, brain, colon, ovary, pancreas, and prostate (Al-Hajj
et al., 2003; Li et al., 2007; O’Brien et al., 2007; Singh et al.,
2003; Zhang et al., 2008b). Thus, like normal tissues, tumors
appear to be organized in a hierarchy that depends on the self-
renewing and ever expanding ‘‘cancer stem cell,’’ which most
likely retains remnants of the normal developmental program.
In support of this model, cancer cells frequently exhibit stem
cell-like gene expression and chromatin structure signatures
(Ben-Porath et al., 2008; Widschwendter et al., 2007). This
predicts similarities in the genes that determine self-renewal
of normal and cancer stem cells and highlights the importance
of identifying the key components regulating this function. Asdetailed below, the Polycomb Group (PcG) genes represent
prime candidates for determining activity of normal and cancer
stem cells. In this review, we discuss the proposed function of
PcG proteins in stem cell activity with a particular focus on their
role in cell-cycle regulation, differentiation, apoptosis, and
senescence. We also briefly describe the growing importance
of PcG genes in cancer development.
Polycomb Complexes
PcG genes were identified in Drosophilamore than 30 years ago
as regulators of anterior-posterior body patterning through the
repression of Hox genes. They have since been recognized as
global epigenetic transcriptional repressors and key regulators
of cell fate (reviewed in Schwartz and Pirrotta, 2007). The Poly-
comb family comprises a structurally diverse set of proteins
which assemble into chromatin-associated complexes. The
composition of these complexes is variable and context-depen-
dent (e.g., differentiation status). However, in mammals, two
main families of PcG chromatin-modifying complexes, named
Polycomb Repressive Complexes 1 and 2 (PRC1, PRC2) have
been identified. The core of the PRC1 complex includes one
subunit of the PCGF, CBX, PHC, SCML, and RING1 paralog
groups (Figure 1, right panel) (Levine et al., 2002; Valk-Lingbeek
et al., 2004). The RING1 protein hasmonoubiquitylation E3 ligase
activity specific for the lysine 119 of H2A (H2AK119ub), a mark
associated with repressive chromatin structure (de Napoles
et al., 2004; Wang et al., 2004). Although less well characterized,
L3MBTL and SFMBT proteins are also found in PRC1
complexes, whereas ASXL1 was recently identified in the new
Polycomb Repressive H2A Deubiquitinase complex (Grimm
et al., 2009; Ohtsubo et al., 2008; Peterson et al., 2004; Peterson
et al., 1997; Sa´nchez et al., 2007; Scheuermann et al., 2010). The
core of PRC2 complexes comprises SUZ12, one of the EED
isoforms and the histone methyltransferase EZH1 or EZH2,
which catalyze the trimethylation of lysine 27 of histone H3
(H3K27me3), another typical epigenetic silencingmark (Figure 1,
left panel) (Cao et al., 2002; Cao and Zhang, 2004; CzerminCell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc. 299
Figure 1. Diversity of PRC1 and PRC2
Complexes Formed by Vertebrate PcG
Proteins
Subunits of the PRC1 (right panel) and PRC2 (left
panel) complexes are indicated. The Drosophila
homolog of each subunit is indicated in light
blue. Multiple combinations of paralog subunits
can generate a diversity of PRC1 and PRC2
complexes, which likely have specific and shared
functions. Some subunits seem to be present
in substoichiometric amounts and interact with
the PcG complexes in a cell-context-dependent
manner. The core subunits and the substoichio-
metric subunits are identified. The contacts illus-
trated in the diagrams are not intended to repre-
sent the actual interactions. Involvement of EPC
and ASXL subunits with PRC2 or PRC1 complexes
is still unclear and requires further investigations.
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PRC2-associated PCL proteins are not essential for complex
formation and stability but are required for enhancement of its
methyltransferase activity (Nekrasov et al., 2007; Sarma et al.,
2008). Similarly, RBBP4/7 and JARID proteins are cofactors
that help to recruit and modulate the enzymatic activity of
PRC2 (Cao et al., 2002; Kuzmichev et al., 2002; Landeira et al.,
2010; Pasini et al., 2008; Peng et al., 2009; Shen et al., 2009).
The incompletely characterized PcG protein EPC1, which was
found in a repressive E2F6-EZH2 complex, can also be consid-
ered as an additional PRC2-associated protein (Attwooll et al.,
2005). When targeted to specific loci, PcG complexes repress
gene expression mainly through epigenetic modification of
histone tails and compaction of chromatin. The current model
of gene silencing by PcG complexes is summarized in Figure 2.
Detailed information about the biochemical characterization
and recruitment of PcG complexes to target genes can be found
in other recent reviews (Surface et al., 2010; Bracken and
Helin, 2009; Schuettengruber and Cavalli, 2009; Simon and
Kingston, 2009).
During the evolution from invertebrates to vertebrates the
number of PcG genes underwent significant expansion, rising
from approximately 15 in Drosophila to 37 in Mouse and
Humans. The apparent gene duplications that occurred, most
notably in mammals, resulted in alternative paralogous subunits
that diverged in their structural domains (Kerppola, 2009;
Whitcomb et al., 2007). In some situations, this structural diver-
sification confers to paralogs the ability to execute novel
activities. For example, expression of the PRC1 protein BMI1
promotes cell proliferation and is essential for maintenance of
cancer cells (Lessard and Sauvageau, 2003), while its paralog
PCGF2/MEL18 (78% amino acid similarity; 97% similarity for
RING domain) blocks cell proliferation and has tumor suppres-
sive functions (Guo et al., 2007; Tetsu et al., 1998). Underlying
the complexity of PcG biology, accumulating evidence indicates
the existence of multiple PRC1 and PRC2 complexes whose
specific function is defined by the activity of the distinct paralogs
that participate in these complexes (Figure 1). A good character-
ization of these different PcG complexes and their specific or
shared functions is greatly lacking, which impedes our ability
to uncover the precise roles PcG play in stem cell activity and
cancer development.300 Cell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc.PcG and Regulation of Cell-Cycle Progression
Accumulating evidence indicate that PcG proteins play impor-
tant functions in multiple cell cycle checkpoints (Figure 3).
G0/G1Transition
Integration of diverse metabolic, environmental, and stress
signals dictates whether cells remain quiescent (G0) or enter
the cell cycle. No role has been ascribed yet to PcGs in G0/G1
transition. However, expression levels of the PRC2 proteins
EZH2 and SUZ12 are greatly reduced in serum-starved nondi-
viding fibroblasts and rapidly increase as they enter cell cycle,
whereas EZH1 levels are not affected (Bracken et al., 2003;
Pasini et al., 2004). It will be important to determine whether
this differential regulation of PcG protein levels also character-
izes somatic stem cells and what role these changes play in their
G0/G1 transition.
G1/S Checkpoint
Regulation of the G1/S transition occurs mainly through the
INK4A-pRB/E2F pathway. The PcG-mediated repression of
the p16Ink4a/p19Arf locus is essential for G1/S progression
(Figure 3A). The PRC1 proteins BMI1, PCGF1, PCGF2/MEL18,
CBX2, CBX7, CBX8, RING1B, and the PRC2 proteins EED,
SUZ12, and EZH2 have been shown in multiple cell types to
bind the p16Ink4a/p19Arf promoter directly and repress this locus
(Gil and Peters, 2006; Maertens et al., 2009). EZH2 also binds to
and trimethylates H3K27 in the p15Ink4b promoter (Kheradmand
Kia et al., 2009). By repressing these CDK inhibitors, the PcG
proteins enable activation of the Cyclin D-CDK4/6 complex
and consequently progression through the G1 phase of the cell
cycle. Stress signals appear to displace PcG complexes from
the promoters of these CDK inhibitors, allowing their expression,
which subsequently blocks cells in G1.
The role of PcG proteins at the G1/S checkpoint is not
restricted to repressing Ink4 CDK inhibitors. PcG complexes
also require an intact pRB-E2F complex to repress a subset of
cell-cycle genes (Blais et al., 2007). BMI1, RING1B, and SUZ12
bind the p16Ink4a locus in a pRB-dependent manner, and
PRC2-dependent trimethylation of H3K27 at this locus requires
an active pRB protein, indicating a regulatory feedback loop
between p16INKA expression and pRB-E2F-PcG complexes
(Kotake et al., 2007). Multiple PcG proteins directly interact
with and modulate the activity of pRB-E2F. In fly and mammals,
physical interaction between L3MBTL1 and pRB-E2F appears to
Figure 2. Coordinated Epigenetic Silencing Activity of PcG
Complexes
Following recruitment of the PRC2 complex to chromatin, the histone methyl-
transferase EZH1/2 catalyzes the trimethylation of the lysine 27 of histone H3
(H3K27me3). Subsequent recruitment of the PRC1 complex occurs in part
through affinity binding of the chromodomain of the CBX subunit to the
H3K27me3 covalent mark. The PRC1 RING1 E3 ligase thenmonoubiquitylates
the lysine 119 of histone H2A (H2AK119ub1), which was proposed to consoli-
date transcriptional repression by preventing access to chromatin remodelers,
inhibiting RNA polymerase II-dependent transcriptional elongation and facili-
tating chromatin compaction (Francis et al., 2004; Zhou et al., 2008). PRC1
has also been reported to be targeted to chromatin independently of PRC2
(Boyer et al., 2006; Ku et al., 2008; Schoeftner et al., 2006). The ASXL subunit
has recently been found to be involved in a H2A deubiquitinase complex
required for PcG-mediated repression, but its precise role remains unclear.
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E2F2-pRB target gene crucial for S phase initiation (Lu et al.,
2007; Trojer et al., 2007). Moreover, EZH2 and HDAC1 compete
for interaction with pRB2/p130, indicating that PRC2 partici-
pates in the regulation of pRB/E2F activity (Tonini et al., 2004).
Interestingly, E2Fs bind to and activate the Ezh2 and Eed
promoters, indicating the presence of a regulatory feedback
loop between PcG and pRB-E2F proteins (Bracken et al.,
2003). Prohibitin (PHB), an antiproliferative protein that interacts
with E2F-pRB and p53, represses E2F target genes by recruiting
corepressors and RING1B/PRC1 complexes. This latter interac-
tion is essential for the transcriptional repressive function of
PHB, and knockdown of PHB results in reduction of RING1B
levels and increase in p16Ink4a expression (Choi et al., 2008).
Thus, RING1B and PHB directly interact with and inhibit
E2F1’s transcriptional activity. Curiously, they also indirectlypromote E2F1 activity by repressing p16Ink4a expression, which
allows Cyclin D-CDK4/6-mediated phosphorylation of pRB and
E2F1 release. This dual function could serve as a fine-tuning
system for G1/S transition in response to mitogenic signals.
S Phase
The PRC1 complex has been implicated in regulation of S phase
initiation. Within the PRC1 complex, SCMH1 directly interacts
with Geminin, an inhibitor of the DNA replication licensing factor
CDT1 (Figure 3B). The PRC1 complex, comprising PHC1,
SCMH1, RING1B, and BMI1, exerts E3 ubiquitin ligase activity
on Geminin. PRC1-induced ubiquitination of Geminin leads
to its proteasome-mediated degradation and to initiation of
S phase entry and/or release of stalled DNA replication forks
(Luo et al., 2004; Ohtsubo et al., 2008). Accordingly, Phc1 defi-
ciency impairs the ubiquitin-proteasome-mediated degradation
of Geminin and blocks initiation of DNA replication. Interestingly,
this regulatory role in S phase does not involve the standard
chromatin-associated function of the PRC1 complex but, rather,
a PRC1-mediated post-translational modification of a nonhis-
tone protein.
As mentioned previously, L3MBTL1 represses expression of
the cyclin E gene. In addition, L3MBTL1 physically interacts
with the methyltransferase PRSET7 (Kalakonda et al., 2008).
This latter protein interacts with PCNA, localizes to sites of
DNA synthesis, and regulates the progression of replication
forks. Knockdown of PRSET7 leads to loss of PRSET7-associ-
ated H4K20me1 marks, improper DNA replication, and massive
occurrence of DNA double-strand breaks (Huen et al., 2008;
Jørgensen et al., 2007; Tardat et al., 2007). Interestingly,
L3MBTL1 levels increase during cell-cycle progression to peak
in G1/S and S (Kalakonda et al., 2008). L3MBTL1 binds to the
PRSET7-dependent H4K20me1 modification, and its accumula-
tion mirrors the presence of this mark during S phase. Although
it remains to be proven, it appears that L3MBTL1 and PRSET7
may cooperate in regulating the progression of DNA replication
forks, and it would be important to find out whether, in this
context, L3MBTL1 and PRESET7 act as components of the
PRC1 complex.
Further evidence suggests that PRC1 and PRC2 complexes
may control the timing of DNA replication. During S phase,
PRC1 proteins are bound to chromatin and to newly replicated
DNA. They also appear to inhibit DNA and chromatin replication
in vitro (Francis et al., 2009). Interestingly, BMI1 interacts with
CDC6, a protein essential for the assembly of the pre-replicative
complex at origins of DNA replication. CDC6 represses p16Ink4a/
p19Arf in a Bmi1-dependent manner (Agherbi et al., 2009).
In addition, the PRC2 protein EZH2 colocalizes with PCNA at
foci of ongoing DNA replication, and the PRC2-mediated
H3K27me3 modifications positively correlate with late replica-
tion of large DNA segments (Birney et al., 2007; Hansen et al.,
2008) (Figure 3B).
G2/M and Spindle Checkpoints
Triggering of M phase is under the control of the Cyclin B/CDK1
complex while control of chromosome segregation is regulated
by the APC/CDC20 complex. Following stress signals, progres-
sion into mitosis can be blocked by association of pRB with
E2F, CtBP, and the PRC1 proteins CBX4 and RING1, which
together bind the promoters and repress the expression of the
cyclin A and Cdk1 genes (Dahiya et al., 2001). Polycomb andCell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc. 301
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Figure 3. Regulation of Cell-Cycle
Checkpoints and DNA Damage Repair
Pathways by PcG
(A) The essential role of PcG proteins in somatic
stem cell self-renewal is multifaceted. It involves
the regulation of several cell-cycle checkpoints,
DNA damage repair pathways, control of dif-
ferentiation, and prevention of senescence
and apoptosis programs. Cell-cycle regulators
directly interacting with or repressed by PRC1
and/or PRC2 proteins are indicated in green
(PRC1), purple (PRC2), and red (PRC1 and
PRC2). The question mark indicates that the role
of PcG proteins in the process remains to be
confirmed.
(B) PRC1 proteins directly interact with Geminin
and mediate its degradation, thereby stabilizing
the DNA replication licensing factor CDT1. PcG
proteins also interact with CDC6, colocalize with
PCNA, and associate with late DNA replication
origins.
(C) PcG proteins play an important role in main-
taining genome integrity by regulating and inter-
acting with multiple proteins and long noncoding
RNAs (lincRNA) involved in DNA damage repair
pathways. They also appear to participate in reactive oxygen species metabolism. The asterisk indicates that the involvement of the PRC1 complex in
DNA damage-induced monoubiquitylation of lysine 119 of histone H2A (H2AK119ub1) remains unclear. The color code in (B) and (C) is the same as in (A).
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first by enabling G1/S progression through repression of the
p16Ink4a/p19Arf locus and then by arresting cells in G2/M through
repression of cyclin A and Cdk1 (Figure 3A). Moreover, the p53-
induced Cip/Kip CDK inhibitors, which act at both the G1/S and
the G2/M transition, are also regulated by PcG proteins. EZH2
was reported to bind and repress the p57Kip2 locus in breast
cancer cells (Yang et al., 2009), whereas p21Cip1 is repressed
by BMI1 or its paralog PCFG1 (Fasano et al., 2007; Gong
et al., 2006). Accordingly, knockdown of p21Cip1 partially
rescues the proliferative defects and the decreased frequency
and size of Bmi1-deficient neurospheres.
In primitive hematopoietic cells, BMI1 interacts with the
atypical ubiquitin E3 ligase E4F1 and triggers its degradation
(Chagraoui et al., 2006). E4F1 is a tumor suppressor that inter-
acts with p53 and pRB and activates both pathways (Fajas
et al., 2000; Le Camet al., 2006) (Figure 3A). E4f1 null cells exhibit
mitotic progression and chromosomal segregation defects,
while ectopic expression of E4f1 results in inhibition of the G1/
S transition and cytokinesis defects. Importantly, loss of E4F1
function is sufficient to rescue the clonogenic and repopulating
ability of Bmi1 null hematopoietic stem cells (HSCs) in
a p16Ink4a/p19Arf- and p53-independent manner. The mecha-
nism of this rescue is still unknown, but it will be important to
test whether this rescue is due to release of the G1/S or G2/M
checkpoints or to some novel function(s) of E4F1.
Redistribution of PHC1, RING1B, BMI1, and PCGF6 from
chromatin to the cytoplasm has been detected in human cells
during mitosis (Akasaka et al., 2002; Miyagishima et al., 2003).
Interestingly, both BMI1 and PCGF6 are specifically phosphory-
lated in G2/M, suggesting that post-translational modification of
these proteins might regulate their functions and their associa-
tion with chromatin (Akasaka et al., 2002; Voncken et al.,
1999). PCGF6 can be phosphorylated in vitro by CDK7, a kinase
required during G2 for Cyclin B/CDK1 complex assembly and
M phase entry (Akasaka et al., 2002). However, if and how the302 Cell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc.cell-cycle phase-specific phosphorylations affect the PRC1
complex activity remains to be elucidated. Recent studies also
revealed that heterozygous mutants of Ph-p, a Drosophila
homolog of PHC, display mitotic chromosome segregation
defects in fly embryos and impaired chromatin condensation
in imaginal discs. PH-p does not localize to chromatin during
M phase but is required for mitosis as suggested by formation
of chromatin bridges and chromosome breakage observed in
mutant flies (Beck et al., 2010; O’Dor et al., 2006). Interestingly,
heterozygous mutants of other PRC1 genes (Pc, Psc, Asx) also
display chromatid segregation defects, whereas impaired chro-
matin condensation and misalignment of chromosomes at the
metaphase plate have been observed in E(z) mutants (O’Dor
et al., 2006). In contrast to other PRC1 proteins, human
L3MBTL1 associates with condensed mitotic chromosomes,
and its overexpression leads to chromosome segregation
defects, failure in cytokinesis, and the formation of multinucle-
ated cells (Koga et al., 1999). PRSET7 also remains associated
with chromosomes during mitosis and appears to be required
for chromosome condensation (Oda et al., 2009; Rice et al.,
2002). As mentioned previously, these two proteins interact
together, suggesting they may function cooperatively during
both S phase and mitosis.
Two recent studies provided potential novel functions for
PCGF2/MEL18 in regulating the G2 and M phases. PCGF2/
MEL18 inhibits sumoylation of the heat shock factor HSF2 by
binding to and inhibiting the UBC9 E2 conjugating enzyme.
HSF2 binds the promoter of other heat shock genes during
mitosis. In M phase, PCGF2/MEL18 dissociates from HSF2,
which renders it susceptible to sumoylation. This enables the
interaction of HSF2 with the CAP-G subunit of the condensing
complex during gene bookmarking, an epigenetic memory
system that allows transmission of the marks that denote active
genes or genes poised for activation to daughter cells (Zhang
et al., 2008a). The anti-SUMO E3 activity of PCGF2/MEL18
also affects RANGAP1, a Ran GTPase-activating protein
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assembly. In contrast to HSF2, the PCGF2/MEL18-RANGAP1
interaction increases duringmitosis, which prevents sumoylation
of RANGAP1 (Zhang and Sarge, 2008). Interestingly, sumoyla-
tion of RANGAP1 is required for its association with RANBP2
and its localization to the spindle and kinetochores (Joseph
et al., 2002). This pathway may thus provide a way to create
a Ran-GTP gradient implicated in the assembly and orientation
of the mitotic spindle (Clarke and Zhang, 2008). Disruption of
the SUMO1-RANGAP1-RANBP2 complex leads to chromo-
some misalignments and segregation defects, a phenotype
reminiscent of that observed in Drosophila PcG mutants (Beck
et al., 2010; Joseph et al., 2002; O’Dor et al., 2006).
PcG AND DNA Damage Repair
Defects in the DNA damage response have been widely associ-
ated with aging, stem cell defects, and cancer (Ito et al., 2004;
Nijnik et al., 2007; Rossi et al., 2007; Ruzankina et al., 2007).
According to recent data, PcG proteins play a role in DNA
damage repair (Figure 3C). The first observations were reported
by Zeidler et al., who found that overexpression of EZH2 in
human mammary epithelial cells leads to a drastic decrease in
expression of multiple RAD51 paralogs required for homologous
recombination double-strand break (DSB) repair. Overexpres-
sion of EZH2 leads to a significant decrease in the numbers
of DNA repair foci, increased aneuploidy, and reduced survival
rates of cells exposed to genotoxic stress (Zeidler et al.,
2005). Recently, the PRC2-associated PCL1/PHF1 protein was
reported to be rapidly recruited to DSBs in a KU70/KU80-
dependent manner. Knockdown of PCL1/PHF1 increases the
frequency of homologous recombination and sensitizes cells to
irradiation. The direct physical interaction of PCL1/PHF1 with
KU70/KU80 and RAD50 proteins strongly suggests that this
PRC2 protein promotes the nonhomologous end joining
(NHEJ) repair pathway (Hong et al., 2008). This possibility is
further supported by studies showing that the PRC2 compo-
nents EZH2 and SUZ12 interact with the poly (ADP-ribose)
polymerase 3 (PARP3) protein, known to interact with compo-
nents of the NHEJ repair pathway (Rouleau et al., 2007). In addi-
tion, 39 different long noncoding RNAs (lincRNA) were reported
to be induced by DNA damage in a p53-dependent manner.
Interestingly, one of them, named TUG1, recruits the PRC2
complex to repress genes that regulate mitosis, spindle forma-
tion, and cell-cycle phasing (Guttman et al., 2009; Khalil et al.,
2009). Given that approximately 20% of the 3,300 identified
lincRNAs were estimated to bind to the PRC2 complex, it is likely
that numerous other lincRNAs interact with PRC2 to mount an
adequate DNA damage response. Interestingly, the PRC1-asso-
ciated monoubiquitination of H2AK119 accumulates at DNA
damage foci, but involvement of the PRC1 ubiquitin E3 ligase
RING1A/B in this process remains to be clearly demonstrated
(Bergink et al., 2006; Zhu et al., 2009).
The PRC1 protein CBX4, a SUMO E3 ligase, interacts with
Centrin-2 and HIPK2, two proteins implicated in DNA damage
repair pathways. Centrin-2 stimulates nucleotide excision repair
(NER) by interacting with XPC, which recognizes DNA lesions.
Sumoylation of Centrin-2 by CBX4 enhances its interaction
with XPC and is essential for its nuclear localization and partici-
pation in NER (Klein and Nigg, 2009). HIPK2 is a kinase involvedin transcriptional repression occurring early after the occurrence
of DNA lesions and implicated in the induction of cell-cycle arrest
and apoptosis. Interaction betweenCBX4 and the DNAdamage-
induced kinase HIPK2 generates an auto-regulatory loop where
HIPK2 controls CBX4 intranuclear localization and phosphory-
lates it at threonine 495. This modification enhances the SUMO
E3 ligase activity, which in turn increases sumoylation of HIPK2
and of CBX4 thereby promotes its DNA damage-induced tran-
scriptional silencing function (Roscic et al., 2006).
Reactive oxygen species (ROS) induce double-strand breaks
and base/nucleotide modifications through DNA oxidation.
Accumulating evidence indicates that oxidative metabolism
plays a crucial role in maintaining the self-renewal properties of
somatic stem cells and that accumulation of high ROS levels
leads to premature differentiation (Jang and Sharkis, 2007;
Owusu-Ansah and Banerjee, 2009). Mice lacking genes involved
in ROS response display genomic instability as well as defects in
the maintenance of HSC quiescence and self-renewal ability (Ito
et al., 2004; Zhang et al., 2007). Interestingly, antioxidant treat-
ment of stem cells with high ROS levels restores their long
term self-renewal potential (Ito et al., 2004; Jang and Sharkis,
2007; Zhang et al., 2007). To date, BMI1 is the only PcG protein
that has been linked to oxidative metabolism. Chatoo et al.
(2009) reported that BMI1 prevents accumulation of ROS in
neurons through the repression of p53’s pro-oxidant activity.
Bmi1 deficiency leads to impaired mitochondrial function and
a marked increase in ROS levels, which in turn activate the
ROS-mediated DNA damage response in a p16Ink4a/p19Arf-inde-
pendent manner. Treatment with antioxidants or abrogation of
the ATM-dependent DNA damage checkpoint extends the
survival ofBmi1/mice and rescues themajority of their cellular
defects. However, long-term repopulation potential of hemato-
poietic stem cells remains severely impaired (Liu et al., 2009).
Although these observations argue against the possibility that
defects of Bmi1/ HSC result from ROS-induced activation of
the DNA damage checkpoint, they do not exclude the possibility
that repair and recovery of DNA lesions may be affected in the
absence of BMI1. Together, these studies indicate that proteins
from both PRC1 and PRC2 are involved in different DNA damage
pathways and play important roles in mounting an adequate
repair DNA damage response to maintain genome integrity.
PcG as Regulators of Cell Fate and Differentiation
The role of PcG proteins in stem cell fate is firmly established
(reviewed in Surface et al., 2010; Sparmann and van Lohuizen,
2006). The genome-wide mapping of PcG target genes in
mammalian and Drosophila cells provided a wealth of informa-
tion about how PcG proteins control differentiation and cell iden-
tity. These studies revealed that PcG complexes bind to and
repress numerous genes encoding key developmental regula-
tors and signaling proteins in embryonic stem cells (ESCs). Inter-
action of PcG proteins with chromatin at these loci is associated
with increased levels of H3K27me3 and H2AK119ub1. Impor-
tantly, these repressed PcG target genes are preferentially acti-
vated during ESC differentiation (Boyer et al., 2006; Bracken
et al., 2006; Lee et al., 2006; Stock et al., 2007; Tolhuis et al.,
2006). This correlates with the loss of PcG binding, loss of the
H3K27me3 and H2AK119ub1 repressive marks, and increase
in the active H3K4me3 modifications. Accordingly, knockout ofCell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc. 303
Figure 4. Resolution of Bivalent Chromatin
Domains and DNA Methylation of PcG
Target Genes
In stem cells, a large proportion of developmental
regulators carry simultaneously both PcG-medi-
ated H3K27me3 and H2AK119ub1 marks and the
H3K4me3 modifications associated with repres-
sive and active chromatin states, respectively.
While remaining silent, these ‘‘bivalent’’ loci are
maintained in a poised state ready for activation,
given that a nonprocessive form of RNA poly-
merase II phosphorylated at serine 5 localizes to
these loci (poised RNA Pol II). Following differenti-
ation, these domains are resolved and retain chro-
matin modifications denoting either completely
repressed (loss of H3K4me3) or activated (loss of
H3K27me3 and H2AK119ub1) state. Resolution
of the ‘‘bivalent’’ domains appears to require the
H3K4me3 JARID demethylases (for repression) or
the H3K27me3 demethylases (JMJD3/UTX) and
MLL complexes (for activation). PRC1 and PRC2
proteins control DNA methylation by directly inter-
acting with DNA methyltransferases (DNMT).
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a loss of H3K27me3 and H2AK119ub1 marks, a spontaneous
increase in developmental gene expression, and consequently,
differentiation defects of embryonic stem cells (Chamberlain
et al., 2008; Pasini et al., 2007; Shen et al., 2008; van der Stoop
et al., 2008). Similar observations have been reported for many
somatic tissues (Ezhkova et al., 2009; Caretti et al., 2004; Hira-
bayashi et al., 2009; Zencak et al., 2005).
Genome-wide chromatin state maps in ESCs revealed
that a large proportion of developmental and tissue specific
genes simultaneously carry the PcG-repressive H3K27me3
and H2aK119ubmarks overlapping with the H3K4me3modifica-
tions associated with an active chromatin state (Bernstein
et al., 2006a; Ku et al., 2008; Stock et al., 2007). These loci,
termed bivalent, are silent or expressed at low levels in pluripo-
tent ESCs. In fact, these loci appear to be in a poised state
ready for activation since the RNA polymerase II phosphorylated
at serine 5, which is associated with paused transcription, also
localizes to these loci (Stock et al., 2007). The PRC1 and PRC2
complexes are bound to these bivalent domains (Ku et al.,
2008). The PRC1-mediated H2AK119ub1 modification rein-
forces the poised RNA polymerase II configuration and deletion
ofRing1a/b leads to the release of the poised RNA polymerase II,
and premature expression of target genes (Stock et al., 2007;
Zhou et al., 2008). In differentiating ESCs, these bivalent
domains are resolved and retain chromatin modifications denot-
ing either completely repressed (loss of H3K4me3) or activated
(loss of H3K27me3 and H2AK119ub1) state (Figure 4). These
bivalent domains are also found in hematopoietic cells, neural
progenitors, and fibroblasts, indicating they are not restricted
to cultured embryonic stem cells (Mikkelsen et al., 2007; Oguro
et al., 2010; Pan et al., 2007; Roh et al., 2006). Deletion of
Bmi1 in hematopoietic stem cells results in the resolution of biva-
lent domains at the Ebf1 and Pax5 B cell lineage-specific genes.
Inappropriate expression of these genes in immature cells leads
to premature lymphoid lineage specification associated with
a loss of stem and progenitor cell populations (Oguro et al.,
2010). More detailed evaluation of the mechanisms that either
establish or resolve these bivalent domains in somatic stem cells304 Cell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc.will provide key information about the role PcG plays in the regu-
lation of cell differentiation.
PcG Proteins and Prevention of Senescence
Senescence is an irreversible phenomenon where cells that
should normally be able to divide (i.e., have not undergone
terminal differentiation) cease to do so. It can result from normal
telomere attrition followingmultiple rounds of divisions (replicative
senescence) or from unrepaired DNA damage (stress-induced
senescence). Progressive reduction of the replicative potential
of stem cells is believed to represent an important factor in the
normal aging of tissues. Induction of a senescence program
requires an intact pRB-p16INK4A pathway because deletion of
p16Ink4a bypasses this process. As mentioned previously, PcG
proteins participate in the transcriptional repressive function of
pRB and directly inhibit expression of the p16Ink4a locus
(Figure 3A). It is, therefore, not surprising that the majority of
PcG genes prevent the onset of the senescent state. Expression
of Bmi1, Cbx2, Cbx7, and Ezh2 is downregulated as cells
approach or enter replicative senescence. This is accompanied
by decreased binding of PcG proteins to the p16Ink4a/p19Arf
promoter, loss of H3K27me3, and upregulation of p16INK4A
and p19ARF expression. Similarly, knockout or downregulation of
these PcG genes by RNAi increases the expression of p16INK4A/
p19ARF and induces premature senescence (Gil and Peters,
2006). Homozygous deletion ofBmi1 in mice leads to a progeroid
phenotype, with prematurely senescent cells and a drastic loss
of hematopoietic and neural stem cells. Deletion of the p16Ink4a/
p19Arf locus partially rescues the HSC and neural cell defects in
these mice (Molofsky et al., 2005; Oguro et al., 2006). However,
whether a combined p15Ink4b and p18Ink4c loss could provide an
improved or even complete rescue of hematopoietic and neural
defects in Bmi1 null mutant mice has not been investigated.
Overexpression of Bmi1, Cbx7, Ezh2, and Cbx8 extends
the replicative lifespan of cells by bypassing senescence in
a pRB-p16INK4A/p19ARF-dependent manner (Gil and Peters,
2006). Importantly, overexpression of Ezh2 prevents HSC
exhaustion after replicative stress induced by serial transplanta-
tions (Kamminga et al., 2006). Prior to transformation, cells
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phase. Direct upregulation of Bmi1 by c-MYC leads to repres-
sion of the p16Ink4a/p19Arf locus and bypasses the oncogene-
induced senescence program, thus promoting tumorigenesis
(Jacobs et al., 1999). Again, it would be critical to determine
the contribution of the other Ink4 members to this important
observation.PcG and Apoptosis
The role of PcG proteins in the regulation of apoptosis has not
been extensively examined. In Drosophila, overexpression of
Ph in imaginal discs induces proliferation associated with
increased JNK-dependent apoptosis (Gonza´lez et al., 2009). In
mammalian cells, the absence of Bmi1 leads to an increase in
apoptosis, whereas its overexpression promotes survival,
protects cells from stress-induced death, and is accompanied
by reduced caspase activity and Poly(ADP-ribose) polymerase
(PARP) cleavage (Lee et al., 2008). In lymphoid cells, BMI1
directly represses the proapoptotic Noxa gene. Importantly,
apoptosis ofBmi1/ lymphoid cells can be rescued by reducing
the expression of Noxa, but not p16Ink4a/p19Arf (Yamashita et al.,
2008). Similarly, Ring1b/ T cells, which are highly susceptible
to apoptosis, express high levels of the proapoptotic gene Bim.
The apoptosis-susceptible phenotype of these cells can be
rescued by reducing the expression of Bim, but not other proa-
poptotic genes such as Perp, Noxa, or Bax, indicating that
RING1B specifically inhibits BIM-mediated apoptosis (Suzuki
et al., 2010). The fact that direct cleavage of RING1B by
Caspases 3 and 9 inhibits its transcriptional repressive activity
(Wong et al., 2007) suggests the presence of a positive feedback
loop in apoptosis signaling pathways. E2F1 can also promote
apoptosis by inducing the expression of Bim. Interestingly,
EZH2, which interacts with E2F1, antagonizes the induction of
E2F1-mediated apoptosis by directly inhibiting expression of
Bim (Wu et al., 2010).PcG and Cancer
The multifaceted functions of PcG proteins in the regulation of
cell-cycle checkpoints, DNA damage repair, cell differentiation,
senescence, and apoptosis makes them prime candidate
cancer stem cell genes.
Deregulation of PcG Gene Expression in Cancer
One of the first indications that PcG proteins play a role in cancer
was the identification of Bmi1 as a c-Myc-collaborating onco-
gene (Haupt et al., 1993; Jacobs et al., 1999). Multiple other
PRC1 genes are aberrantly expressed in a broad spectrum of
human cancers (summarized in Table 1 and Figure 5B, reviewed
in Rajasekhar and Begemann, 2007; Sparmann and van
Lohuizen, 2006). Bmi1 is overexpressed, and its locus amplified
in several human leukemias and solid tumors. BMI1 activity is
crucial for the maintenance of both normal and cancer stem
cells, as the loss of its function leads to progressive depletion
of these cell populations (Lessard and Sauvageau, 2003).
Conversely, the Bmi1 paralog Pcgf2/Mel18 acts as a negative
regulator of cell proliferation and possesses tumor suppressive
functions. Overexpression of Pcgf2/Mel18 impairs proliferation
and leads to G1/S arrest, whereas deletion of this gene promotes
proliferation (Tetsu et al., 1998). In line with this, loss ofPcgf2/Mel18 expression is often found in different types of
human cancers (Table 1).
The PRC2 proteins EZH2, SUZ12 and PCL3/PHF19 are
also overexpressed in a variety of different human cancers
(summarized in Table 1 and Figure 5B, reviewed in Rajasekhar
and Begemann, 2007; Sparmann and van Lohuizen, 2006).
The Ezh2 gene is amplified in many human prostate cancer
cell lines, in 27% of untreated prostate carcinomas, in 80% of
xenografts, and is a good marker for aggressiveness and poor
outcome in prostate and breast cancers (Kleer et al., 2003;
Sarama¨ki et al., 2006; Varambally et al., 2002). More than half
of the hormone-refractory prostate cancers possess increased
copies of Ezh2, which correlates with high expression levels of
this gene. Ezh2 overexpression and amplification is rare in early
stage prostate cancers, but much more common in late stages,
highlighting its potential function in tumor progression (Sarama¨ki
et al., 2006).
Mutations andChromosomeAnomalies of PcG inCancer
Recently, a number of PcG missense mutations and chromo-
somal translocations have been identified in different types of
human cancers (also summarized in Table 1 and Figure 5B).
Somatic Ezh2 mutations and deletions were found in 22% of
germinal center diffuse large B cell lymphomas, 7% follicular
lymphomas, and 12%–23% of patients with myelodysplasic
and myeloproliferative disorders (Ernst et al., 2010; Morin
et al., 2010; Nikoloski et al., 2010). Both monoallelic and biallelic
mutations were found, and almost all are predicted to inactivate
the methyltransferase activity of EZH2. This PcG enzyme, there-
fore, appears to have both oncogenic and tumor suppressive
functions. Supporting this, heterozygous null or homozygous
hypomorphic mutations of Eed in mice increase the incidence
and reduce the latency of lymphoid tumors (Richie et al., 2002;
Sauvageau et al., 2008), indicating a possible tumor suppressive
role for this other PRC2 protein. Importantly, the methyltransfer-
ase activity of EZH2 depends on its interaction with EED, and
mutations in EED have been reported to affect this interaction
(Denisenko et al., 1998; Shumacher et al., 1996; van Lohuizen
et al., 1998). Heterozygosity for a Suz12 allele carrying an inacti-
vating point mutation was also reported to cause an increase
in numbers of platelets, megakaryocytes, and hematopoietic
progenitors. Moreover, HSCs harboring a Suz12 mutation are
more competitive in repopulating the hematopoietic system
than their wild-type counterparts, indicating that SUZ12 nega-
tively regulates HSC/progenitor activity and suggesting a tumor
suppressive role for SUZ12 (Majewski et al., 2008). Together,
these studies indicate that a delicate balance of PRC2 gene
dosage is crucial for homeostasis. Either upregulation or
a decrease in PRC2 activity is sufficient to sensitize cells to trans-
formation, whereas complete absence of PRC2 activity leads to
stem cell extinction (Figure 5A).
The ASXL proteins have been implicated in cancer develop-
ment by recent studies reporting Asxl1 mutations in 17%–25%
of acute myeloid leukemias, 33%–43% of myelomonocytic
leukemias, and 10%–18% of myelodysplasic syndromes and
hyperproliferative disorders (Table 1). The majority of Asxl1
alleles are heterozygous frameshift mutations caused by dupli-
cations, insertions, substitutions, or deletions of nucleotides
and are predicted to encode an ASXL1 protein lacking the
C-terminal region comprising the nuclear receptor box andCell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc. 305
Table 1. Expression, Mutations, and Chromosomal Translocations of PcG Genes in Human Cancers
Aberrant Expression
Subunit Expression Cancer Type
PRC2 Components
Ezh2 overexpression
and/or amplification
B cell non-Hodgkin lymphomas,35 bladder cancers,1,5,29,41 breast cancers,2,5,8,15,27 colon
cancers,5,22 glioblastoma,5 Hodgkin lymphomas,28 oral cancers,5 liver cancers,33 lung
cancers,5 lymphoma,5 mantle cell lymphomas,37 melanomas,2 prostate cancers,2,36
testicular cancers5
Suz12 overexpression
and/or amplification
breast cancers,14 colon cancers,14,42 germinal cell-derived tumors,20 liver cancers,14 lung
cancers,20 mantle cell lymphomas,20 melanomas,20 parathyroid and pituitary adenomas20
Pcl3/Phf19 overexpression colon cancers,39 skin cancers,39 lung cancers,39 rectal cancers,39 cervical cancers,39
uterus cancers,39 liver cancers39
PRC1 components
Cbx7 overexpression follicular lymphoma32
loss pancreatic cancers13
Phc1 loss of heterozygosity acute lymphoblastic leukemias34
Phc3 loss of heterozygosity Osteosarcomas12,17
Bmi1 overexpression
and/or amplification
acute myeloid leukemias,31 breast cancers,30 gastrointestinal tumors,30 lymphomas,3,30,35
medulloblastomas,18 neuroblastomas,26 lung cancers,38,30 parathyroid and pituitary
adenomas30
Pcgf2/Mel18 loss cutaneous squamous-cell carcinomas,30 gynecological tumors,30 prostate cancers30,40
Ring1a loss clear-cell renal-cell carcinomas,30 testicular germ-cell tumors30
Ring1b overexpression bladder cancers,30 breast cancers,30 colon tumors,30 gynecological tumors,30 kidney
cancers,30 larynx cancers,30 livers cancers,30 lung cancers,30 lymphomas,30 melanomas,30
pancreas cancers,30 parathyroid and thyroid cancers,30 prostate cancers,30 skin cancers,30
thymus cancers,30 urinary tract cancers30
Mutations
Subunit Type of Mutation Cancer Type
PRC2 Components
Ezh2 missense diffuse large B cell lymphomas,23 myelodysplasic/myeloproliferative syndromes10,25
Epc1 truncation acute lymphoblastic leukemias24
PRC1 Components
Phc3 missense osteosarcomas9,12
Asxl1 frameshift, truncation acute myeloid leukemias,4,7 myelodysplasic/myeloproliferative syndromes4,6,11
Chromosomal Translocations
Subunit Fusion Gene Partner Cancer Type
PRC2 Components
Suz12 Jazf1 endometrial stromal sarcomas16,19
Pcl1/Phf1 Jazf1, Epc1 endometrial stromal sarcomas21
Epc1 Asxl2 acute lymphoblastic leukemias24
PRC1 Components
Asxl2 Epc1 acute lymphoblastic leukemias24
See Supplemental Information for detailed numerical references.
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Gelsi-Boyer et al., 2009). Interestingly, in acute myeloid
leukemias, ASXL1 and NPM1 mutations appear to be mutually
exclusive, ASXL1 mutations being present in 34% of non-
NPM1-mutated cases (Carbuccia et al., 2010). Moreover,
Asxl/ mice have defects in lymphoid and myeloid progenitor
cell frequency and differentiation, whereas multipotent progen-
itor and HSC populations appear to behave normally (Fisher
et al., 2010). Missense mutations are also found in PHC3 in
osteosarcomas (Deshpande et al., 2007; Iwata et al., 2010).306 Cell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc.More extensive analysis of PcG mutations in human cancers
will likely be revealing.
Some PcG genes are involved in recurrent chromosomal
rearrangements detected in human cancers (see Table 1). In
addition, PcG proteins have been shown to be recruited to target
genes by physically interacting with a number of chimeric fusion
proteins involved in leukemia, such as PLZF-RARA and
TMPRSS2-ERG (Figure 5D) (Boccuni et al., 2003; Boukarabila
et al., 2009; Garcı´a-Cue´llar et al., 2001; Hemenway et al.,
2001; Villa et al., 2007; Yu et al., 2010).
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Figure 5. Deregulation of PcG Activity in
Cancer
(A) Proposed model for PcG gene dosage and its
effect on stem cells and cancer development.
Briefly, adequate PcG gene expression levels
seem to be essential to maintain homeostasis
and normal stem cell function. Gain or loss of
PcG functions, such as deregulated expression
or mutations, lead to increased tumor develop-
ment, possibly by modifying the composition or
perturbing the stoichiometry of the complexes. In
turn, complete ablation of PcG activity appears
to be detrimental and leads to impaired self-
renewal and loss of stem cells.
(B) Schematic representation of the balance
between PcG-mediated H3K27me3 and MLL
complex-mediated H3K4me3 modifications in the
maintenance of a transcriptional program. The
function of many proteins from these complexes
is altered by aberrant expression (yellow star), by
missensemutations (blue star), or by chromosomal
translocations (red star) in human cancers (Agger
et al., 2009; Dalgliesh et al., 2010; Krivtsov and
Armstrong, 2007; van Haaften et al., 2009; Wang
et al., 2009; Xiang et al., 2007), likely leading to
changes in transcriptional programs and cell
states.
(C) Expression of Ezh2 and Bmi1 is regulated at
the post-transcriptional level bymiRNAs, targeting
their 30UTR, leading to transcript degradation.
(D) Multiple chimeric proteins resulting from chro-
mosomal translocations found in human cancers
interact with PRC1 and PRC2 complexes and appear to recruit them to target genes. AF9. ENL and TEL are found in multiple chromosomal translocation-derived
fusion proteins in human cancers. The asterisk indicates that, although actual recruitment of PRC1 by the fusion proteins remains to be proven, the AF9, ENL,
and TEL domains interacting with PRC1 proteins are present in the fusion proteins and are essential for their oncogenic activity (Boccuni et al., 2003; Garcı´a-
Cue´llar et al., 2001; Hemenway et al., 2001).
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Aging is the strongest demographic risk factor for cancer, and
several lines of evidence point to an association between aging
and changes in DNA methylation at specific loci. Epigenetic
silencing by DNA hypermethylation is prevalent in cancers and
represents an efficient mechanism for inactivation of tumor
suppressor genes. Interestingly, PcG target genes identified in
ESCs are more likely to be hypermethlyated in aged somatic
cells (Teschendorff et al., 2010). A large proportion of the PcG
target methylation signature is present in ovarian cancer, follic-
ular lymphoma, and glioblastoma multiforme (Martinez et al.,
2009; O’Riain et al., 2009; Teschendorff et al., 2010). In fact,
the PcG target genes identified in ESCs are 12 times more likely
to be hypermethylated in cancers than non-PcG targets (Ohm
et al., 2007; Widschwendter et al., 2007). A recent study showed
that 50% of genes frequently hypermethylated in colon or pros-
tate cancers are premarked by PcG proteins and by the PRC2-
mediated H3K27me3 mark for de novo methylation in cancer
(Schlesinger et al., 2007). The link between DNA methylation
and polycomb target genes in cancer is further supported by
the fact that PRC2 directly controls DNA methylation through
interaction of EZH2 with the DNA methyltransferases DNMT1,
DNMT3A, and DNMT3B. This interaction allows the recruitment
of DNMTs to PRC2-repressed genes and their subsequent
methylation (Vire´ et al., 2006). The PRC1 proteins CBX4 and
CBX7 also interact with DNMT3B, whereas BMI1 forms a ternary
complex with DNMT1 through direct interaction with the DNMT-
associated protein DMAP1 (Kim et al., 2008; Mohammad et al.,
2009; Negishi et al., 2007). It was estimated that approximately47% of DNMT3B target genes are bound by PRC1 and PRC2
and that DNMT3B-PcG-bound genes in normal cells are good
predictors of epigenetically silenced loci in colon cancer (Jin
et al., 2009). Since most of the PcG targets are lineage and
differentiation determinants, these studies suggests that gradual
de novo DNA methylation of PcG targets locks cells in an undif-
ferentiated state and predisposes them tomalignant transforma-
tion (Figure 4).
Recently, many large intervening noncoding RNAs (lincRNA) in
the Hox loci have been found to be deregulated during progres-
sion of breast cancer. The lincRNA HOTAIR, which recruits the
PRC2 complex to silence the HoxD cluster, is overexpressed
in primary breast tumors and metastases. In fact, high HOTAIR
levels appear to be a good indicator of metastatic progression,
and its knockdown decreases cancer invasiveness, especially
in cells expressing high levels of PRC2 proteins (Gupta et al.,
2010; Rinn et al., 2007). Conversely, ectopic expression of
HOTAIR increases invasiveness and metastasic potential of
epithelial cancer cells and induces relocalization of the PRC2
complex to bind target genes in a pattern similar to that observed
in embryonic fibroblasts. The resulting differential gene expres-
sion pattern is likely responsible for the invasive phenotype
because reduction of PRC2 activity in HOTAIR-overexpressing
cells inhibits metastasis (Gupta et al., 2010). It is likely that
numerous other lincRNAs are also deregulated in cancers, thus
generating a new mechanism to redirect PRC2 complex activity
and ‘‘reprogram’’ cells to an undifferentiated and/or malignant
state. Interestingly, interaction between the lincRNA ANRIL and
the PRC1 protein CBX7 in prostate cancer cells has recentlyCell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc. 307
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p19Arf locus (Yap et al., 2010). Since all CBX proteins have
sequence-specific RNA binding activity, they also likely interact
with multiple lincRNAs and thereby target the PRC1 complex to
specific loci (Bernstein et al., 2006b).
In recent years, small noncoding RNAs have been recognized
as major players in regulatory pathways, and many of them
are deregulated in cancers. Multiple miRNAs are repressed in
ESCs and marked by H3K27me3 modification, indicating that
PRC2 complexes regulate their expression (Marson et al.,
2008). In addition, several miRNAs were found to bind PcG tran-
scripts and inhibit their expression (e.g., mir-26a and mir-214
target Ezh2 transcript [Juan et al., 2009; Sander et al., 2008])
(Figure 5C). Interestingly, MYC decreases the expression of
mir-26a and, thereby, contributes to tumorigenesis by allowing
expression of Ezh2 (Sander et al., 2008). mir-101 targets the
30UTR of Ezh2mRNA and promotes its degradation. Expression
of this miRNA is downregulated in bladder transitional cell
carcinoma, hepatocellular carcinoma, and prostate tumors,
which correlates with high Ezh2 levels (Friedman et al., 2009;
Su et al., 2009; Varambally et al., 2008). Almost 40% of prostate
cancers and 67% of metastatic stage tumors harbor loss of one
or both mir-101 alleles. Overexpression of mir-101 inhibits prolif-
eration and reduces the invasiveness potential and colony
formation activity of cancer cells, a phenotype similar to that
found with Ezh2 knockdown (Cao et al., 2010; Friedman et al.,
2009; Varambally et al., 2008).
The PRC1 gene Bmi1 is also targeted by multiple miRNAs.
Expression of Bmi1 is post-transcriptionally inhibited by mir-
128, mir-183, mir-200c, and mir-203, which target the 30UTR
of the transcript. The mir-203 locus is silenced by DNA methyl-
ation in hepatocellular carcinoma and squamous cell carcinoma
of the esophagus (Furuta et al., 2010; Kozaki et al., 2008). Simi-
larly, mir-200 and mir-183 are often suppressed by DNA meth-
ylation in invasive cancers, providing a link between miRNAs
and the deregulation of PcG in cancers. Human glioblastomas
display reduced levels of mir-128, whereas ectopic expression
of mir-128 inhibits glioma cell proliferation and xenograft
growth. Bmi1 downregulation by mir-128 in glioma cells leads
to a decrease in H3K27me3 levels, upregulation of p21Cip1,
and a block in self-renewal (Godlewski et al., 2008). Normal
mammary and breast cancer stem cell populations show
reduced expression of mir-183 and mir-200 family members,
resulting in increased Bmi1 levels. In addition to inhibiting the
ability of normal mammary stem cells to form mammary ducts,
expression of mir-200c suppresses breast cancer stem cell
proliferation, clonogenicity, and tumorigenic potential (Shimono
et al., 2009). Recently, a link between miRNA, Bmi1, and
epithelial-mesenchymal transition (EMT) was also established.
Carcinoma invasiveness and metastasic spread is promoted
by the establishment of an embryonic EMT program. Expres-
sion of the ZEB1 protein activates epithelial-mesenchymal
transition (EMT) and contributes to the maintenance of stem
cell self-renewal. This protein also suppresses expression of
mir-200c, mir-203, and mir-183, which results in high levels of
BMI1. Highly invasive tumors express high levels of ZEB1,
which appears to be essential for the expansion of primary
and metastic pancreatic and colorectal tumors (Wellner et al.,
2009).308 Cell Stem Cell 7, September 3, 2010 ª2010 Elsevier Inc.Concluding Remarks
Through chromatin silencing and other non-histone functions,
PcG complexes are involved in the regulation of multiple molec-
ular programs essential for stem cell activity. Such programs
involve cell cycle checkpoints and progression, DNA damage
repair, differentiation, apoptosis and senescence. Aberrant
expression, inactivating mutations, chromosomal translocations
and recruitment of PcG proteins and complexes by chimeric
proteins or lincRNAs are observed in human tumors. The
frequency of these newly reported mutations/anomalies now
suggests that deregulation of PcG activity is central to cancer
development and cancer stem cell biology. A clear picture of
the exact regulatory events involving PcG complexes in stem
cell self-renewal and cancer is hindered by the multiplicity of
PcG complexes and by the distinct functions of the different
PcG proteins within these complexes. Future studies will have
to address this issue.SUPPLEMENTAL INFORMATION
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